Cervomed Inc (CRVO)
$11.08 -0.16 (-1.42%)Market Cap | 86.85M |
Revenue (ttm) | 9.74M |
Net Income (ttm) | -16.29M |
EPS (ttm) | N/A |
PE Ratio | 0.00 |
Forward PE | N/A |
Profit Margin | -167.25% |
Debt to Equity Ratio | 0.00 |
Volume | 1,248,500 |
Avg Vol | 5,691,050 |
Day's Range | N/A - N/A |
Shares Out | 8.70M |
Stochastic %K | 52% |
Beta | 0.18 |
Analysts | Strong Sell |
Price Target | $17.00 |
Latest News on CRVO


Mar 25, 2025, 8:00 AM EDT - 10 days ago
CervoMed Announces Oral Presentation at 19th International Conference on Alzheimer's and Parkinson's Diseases and Related Neurologic Disorders (AP/PD™)

Mar 22, 2025, 2:55 AM EDT - 13 days ago
CervoMed: Extension Study Data In Dementia With Lewy Bodies Is Potentially Exciting, With Caveats

Mar 10, 2025, 4:05 PM EDT - 25 days ago
CervoMed Announces Positive Results from the Extension Phase of its Phase 2b Clinical Study of Neflamapimod in Patients with Dementia with Lewy Bodies

Jan 29, 2025, 8:00 AM EST - 2 months ago
CervoMed to Present at the 8th International Lewy Body Dementia Conference

Dec 12, 2024, 7:00 AM EST - 4 months ago
CervoMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dec 10, 2024, 11:37 AM EST - 4 months ago
CervoMed's Dementia Candidate Fails In Mid-Stage Study, Stock Plummets

Dec 10, 2024, 10:10 AM EST - 4 months ago
CervoMed's stock craters 77% after failed trial of treatment for rare brain disease

Dec 10, 2024, 7:33 AM EST - 4 months ago
CervoMed's dementia drug fails to meet mid-stage trial goals

Dec 10, 2024, 7:00 AM EST - 4 months ago
CervoMed Announces Topline Data from RewinD-LB Phase 2b Clinical Trial in Patients with Dementia with Lewy Bodies

Nov 27, 2024, 7:00 AM EST - 4 months ago
CervoMed Announces Orphan Drug Designation Granted to Neflamapimod by U.S. Food and Drug Administration for the Treatment of Frontotemporal Dementia

Nov 12, 2024, 7:00 AM EST - 5 months ago
CervoMed Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

Nov 8, 2024, 9:55 AM EST - 5 months ago
CervoMed Awarded the Prix Galien USA 2024 Prize for Best Startup

Nov 4, 2024, 8:00 AM EST - 5 months ago
CervoMed Announces Key Takeaways from Oral Presentations at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD)

Oct 29, 2024, 8:00 AM EDT - 5 months ago
CervoMed to Deliver Oral Presentation at the 8th International Lewy Body Dementia Conference

Oct 2, 2024, 8:00 AM EDT - 6 months ago
CervoMed to Participate in 3rd Annual ROTH Healthcare Opportunities Conference

Aug 22, 2024, 8:00 AM EDT - 8 months ago
CervoMed Featured in Fortune for Advances in the Treatment of Dementia with Lewy Bodies

Jul 30, 2024, 8:00 AM EDT - 8 months ago
CervoMed to Participate in The Canaccord Genuity 44th Annual Growth Conference

Jul 11, 2024, 8:51 AM EDT - 9 months ago
CervoMed to Host Virtual KOL Event on Neflamapimod for Dementia with Lewy Bodies on July 23, 2024

Jun 11, 2024, 8:00 AM EDT - 10 months ago
CervoMed Announces Completion of Enrollment in Phase 2b RewinD-LB Clinical Trial of Neflamapimod for the Treatment of Patients with Dementia with Lewy Bodies

May 20, 2024, 8:00 AM EDT - 11 months ago
CervoMed to Appoint William Elder as Chief Financial Officer

May 15, 2024, 8:00 AM EDT - 11 months ago
CervoMed Reports First Quarter 2024 Financial Results and Provides Corporate Updates

Apr 2, 2024, 2:59 AM EDT - 1 year ago
CervoMed: H2 2024 Data For DLB Program A Major Inflection Point

Apr 1, 2024, 8:00 AM EDT - 1 year ago
CervoMed Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates

Mar 28, 2024, 8:30 AM EDT - 1 year ago
CervoMed Announces Up to $149.4 Million Private Placement Financing Joined by Leading Healthcare Investors


Feb 21, 2024, 8:00 AM EST - 1 year ago
CervoMed to Participate in the BIO CEO and Investor Conference


Feb 7, 2024, 8:30 AM EST - 1 year ago
CervoMed Announces Appointment of Industry Leader Joshua Boger, Ph.D., as Chair of the Board

Nov 13, 2023, 7:00 AM EST - 1 year ago
CervoMed Reports Third Quarter 2023 Financial Results and Business Highlights



Oct 18, 2023, 7:00 AM EDT - 1 year ago
CervoMed Announces Oral Presentation at CTAD 2023 Highlighting Phase 2b Neflamapimod Program for the Treatment of Patients with Dementia with Lewy Bodies

Oct 5, 2023, 7:00 AM EDT - 1 year ago
CervoMed to Present at the 2023 Roth Healthcare Opportunities Conference

Sep 5, 2023, 7:00 AM EDT - 1 year ago
CervoMed to Present at H.C. Wainwright 25th Annual Global Investment Conference

Aug 15, 2023, 4:01 PM EDT - 1 year ago
Diffusion Pharmaceuticals Stockholders Approve Merger with EIP Pharma

Apr 3, 2023, 2:13 PM EDT - 2 years ago
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates HSKA, LSI, EXR, DFFN


Mar 30, 2023, 7:00 AM EDT - 2 years ago
EIP Pharma and Diffusion Pharmaceuticals Announce Merger Agreement to Create Leading CNS-focused Company Treating Neurodegenerative Diseases

Dec 16, 2022, 6:30 AM EST - 2 years ago
Diffusion Pharmaceuticals Announces Agreement with LifeSci Special Opportunities


Nov 14, 2022, 4:01 PM EST - 2 years ago
Diffusion Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update

Nov 14, 2022, 6:30 AM EST - 2 years ago
Diffusion Pharmaceuticals Sees Significant Progress in its Strategic Review Process

Oct 25, 2022, 6:30 AM EDT - 2 years ago
Diffusion Pharmaceuticals Announces Strategic Review Process to Evaluate Value-Enhancing Alternatives including Opportunities to Better Leverage TSC